Possible explanations include higher or lower affinities of different binding sites for HIF-1α, sequence context or chromatin configuration of the binding sites, different basal levels of expression of HIF-1α target genes in different cancer cells, or differences in experimental protocols from study to study. This evidence concerns the gene HIF1A and cancer.